The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population. - Beyerlin K; Jimenez R; Zangardi M; Fell GG; Edmonds C; Johnson A; Bossuyt V; Specht M; Mulvey TM; Moy B; Ellisen LW; Isakoff SJ; et al. (Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021)